LIVE ATTENUATED AND INACTIVATED INFLUENZA VACCINES: DATA FROM DIRECT COMPARATIVE STUDIES


Cite item

Full Text

Abstract

Comparative evaluation of live attenuated and inactivated influenza vaccines based on data from direct comparative studies is necessary for ensuring the most effective and safe vaccination against influenza. Analysis of direct comparative preclinical and clinical studies of inactivated and live cold-adapted (ca) influenza vaccines showed that published data are inconsistent and limited for some population groups. Live ca vaccines may be promising as an alternative or addition to inactivated vaccines especially for mass vaccination against influenza in children as well as in the elderly when combined with inactivated vaccines. Further studies of inactivated and live ca influenza vaccines in direct comparative studies that control the administration route and vaccine strain production as well as development and confirmation of objective criteria of live attenuated influenza vaccine effectiveness evaluation are necessary.

About the authors

O. S Kashirina

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

Y. M Vasiliev

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

References

  1. Баранцева И.Б., Найхин А.Н., Донина С.А. и др. Гуморальный и местный иммунный ответ на гриппозные вакцины у лиц пожилого и молодого возраста. Вопр. вирусол. 2003, 2: 32-36.
  2. Бурцева Е.И., Обросова-Серова Н.П., Говоркова Е.А. и др. Сравнительное изучение защитных свойств живой рекомбинантной и инактивированной гриппозных вакцин из штамма A/Филиппины/2/82 (H3N2) у детей 8-15 лет. Вопр. вирусол. 1991, 5: 375377.
  3. Васильев Ю.М. Адъюванты гриппозных вакцин - современное состояние. Журн. микробиол. 2010, 1: 100-110.
  4. Гендон Ю.З. Гриппозные вакцины. В: Вакцины и вакцинация: национальное руководство. В.В. Зверев, Б.Ф. Семенов, Р.М. Хаитов (ред.). М., ГЭОТАР-Медиа, 2011.
  5. Гендон Ю.З. Живые холодоадаптированные реассортантные гриппозные вакцины. Вопр. вирусол. 2001, 3: 5-12.
  6. Гендон Ю.З., Каира А.Н., Ельшина Г.А. и др. Массовая вакцинация детей против гриппа снижает заболеваемость рядом болезней невакцинированных пожилых лиц во время гриппозной эпидемии. Журн. микробиол. 2004, 5: 62-67.
  7. Колобухина Л.В., Львов Д.К., Бурцева Е.И. Грипп. В: Медицинская вирусология: руководство. Д. К. Львов (ред.). М., Медицинское информационное агентство, 2008.
  8. Майорова Л.П., Смородинцев А.А. Защитная эффективность сыворотки крови и клеток иммунной системы мышей, иммунизированных живой или инактивированной вируса гриппа. Вопр. вирусол. 1984, 5: 540-543.
  9. Слепушкин А.Н., Обросова-Серова Н.П., Бурцева Е.И. и др. Сравнительное изучение прививочных свойств живой рекомбинантной и инактивированной гриппозных вакцин из штамма A/Филиппины/2/82 (H3N2) у детей 8 - 15 лет. Вопр. вирусол. 1991, 5: 372374.
  10. Ambrose C., Levin M., Belshe R. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Inf. Oth. Resp. Vir. 2011, 5: 67-75.
  11. Ambrose C., Luke C., Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Inf. Oth. Resp. Vir. 2008, 2: 193-202.
  12. Ambrose C., Wu X., Knuf M. et al. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies. Vaccine. 2012, 30: 886-892.
  13. Ashkenazi S., Vertruyen A., Aristegui J. et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr. Infect. Dis. J. 2006, 25: 870-879.
  14. Belshe R., Ambrose C., Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine. 2008, 26 (4): D10-16.
  15. Belshe R., Edwards K., Vesikari T. et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 2007, 356: 685- 696.
  16. Beyer W., Palache A., de Jong J. et al. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine. 2002, 20: 1340-1353.
  17. Clark A., Potter C., Jennings R. et al. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity. J. Hyg. (Lond.). 1983, 90: 351-359.
  18. Clark A., Potter C., Jennings R. et al. A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity. J. Hyg. (Lond.). 1983, 90: 361-370.
  19. Clements M., Betts R., Murphy B. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet. 1984, 1: 705-708.
  20. Clements M., Murphy B. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J. Clin. Microbiol. 1986, 23: 66-72.
  21. Delem A., Van Rensburg W, Flaskett I. Comparison of the protective efficacies of the live vaccine RIT 4025 and an inactivated vaccine against a natural heterologous A/Victoria/3/75 infection. J. Hyg. (Lond.). 1979, 83: 221-229.
  22. Edwards K., Dupont W, Westrich M. et al. A randomised control trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J. Infect. Dis. 1994, 1: 68-76.
  23. Feldman S., Wright P., Webster R. et al. Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus. J. Infect. Dis. 1985, 152: 1212-1218.
  24. Fenton R., Clark A., Potter C. Immunity to influenza in ferrets. XIV: Comparative immunity following infection or immunization with live or inactivated vaccine. Br. J. Exp. Pathol. 1981, 62: 297-307.
  25. Fleming D., Crovari P., Wahn U. et al. CAIV-T Asthma Study Group. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr. Infect. Dis. 2006, 25: 860-869.
  26. Forrest B., Steele A., Hiemstra L. et al. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine. 2011, 29: 3633-3639.
  27. Gorse G., Belshe R., Munn N. Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest. 1991, 100: 977-984.
  28. Gustin K., Maines T., Belser J. et al. Comparative immunogenicity and cross-clade protective efficacy of mammalian cell-grown inactivated and live attenuated H5N1 reassortant vaccines in ferrets. J. Infect. Dis. 2011, 204: 1491-1499.
  29. Harris K., Ream R., Gao J. et al. Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. Virol. J. 2011, 8: 251.
  30. Hoft D., Babusis E., Worku S. et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccinesinduce diverse T-cell responses in young children. J. Infect. Dis. 2011, 204: 845-853.
  31. Huber V., Kleimeyer L., McCullers J. Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine. 2008, 26: 5381-5388.
  32. Jefferson T., Di Pietrantonj C., Rivetti A. et al. Vaccines for preventing influenza in healthy adults. Coch. Database Syst. Rev. 2010, 7: CD001269.
  33. Jefferson T., Rivetti A., Di Pietrantonj C. et al. Vaccines for preventing influenza in healthy children. Coch. Database Syst. Rev. 2012, 8: CD004879.
  34. Johnson P., Feldman S., Thompson J. et al. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J. Med. Virol. 1985, 17: 325-335.
  35. Johnson P., Feldman S., Thompson J. et al. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J. Infect. Dis. 1986, 154: 121-127.
  36. Khan A., Polezhaev F., Vasiljeva R. et al. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J. Infect. Dis. 1996, 173: 453-456.
  37. King J., Gross P., Denning C. et al. Comparison of live and inactivated influenza vaccine in high risk children. Vaccine. 1987, 5: P. 234-238.
  38. Levin M., Song L., Fenton T. et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine. 2008, 26: 4210-4217.
  39. Lobmann M., Delem A., Peetermans J. et al. Laboratory characteristics of an attenuated influenza type A (H3N2) virus ('Alice' strain). J. Hyg. (Lond.). 1976, 77: 181-188.
  40. Luce B., Nichol K., Belshe R. et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24 - 59 months in the United States. Vaccine. 2008, 26: 2841-2848.
  41. Meitin C., Bender B., Small P. Influenza immunization: intranasal live vaccinia recombinant contrasted with parenteral inactivated vaccine. Vaccine. 1991, 9: 751-756.
  42. Moldoveanu Z., Clements M., Prince S. et al. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine. 1995, 13: 1006-1012.
  43. Monto A., Ohmit S., Petrie J. et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N. Engl. J. Med. 2009, 361: 1260-1267.
  44. Ohmit S., Victor J., Teich E. et al. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J. Infect. Dis. 2008, 198: 312-317.
  45. Ohmit S., Victor J., Rotthoff J. et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 2006, 355: 2513-2522.
  46. Osterholm M., Kelley N., Sommer A. et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12: 36-44.
  47. Potter C., Oxford J. Determinants of immunity to influenza infection in man. Br. Med. Bull. 1979, 35: 69-75.
  48. Powers D., Fries L., Murphy B. et al. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J. Clin. Microbiol. 1991, 29: 498-505.
  49. Rhorer J., Ambrose C., Dickinson S. et al. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine. 2009, 27: 1101-1110.
  50. Rudenko L., Slepushkin A., Monto A. et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J. Infect. Dis. 1993, 168: 881-887.
  51. Schiff G., Linnemann C., Shea L. et al. Evaluation of a live, attenuated recombinant influenza vaccine in high school children. Infect Immun. 1975, 11: 754-757.
  52. Slepushkin A., Obrosova-Serova N., Burtseva E. et al. Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia: I. Safety and efficacy in two Moscow schools, 1987/88. Vaccine. 1993, 11: 323-328.
  53. Spencer M., Cherry J., Powell K. et al. Clinical trials with Alice strain, live, attenuated, serum inhibitor-resistant intranasal influenza A vaccine. J. Infect. Dis. 1975, 132: 415-420.
  54. Tarride J., Burke N., Von Keyserlingk C. et al. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. Clinicoecon. Outcomes Res. 2012, 4: 287-298.
  55. Treanor J., Kotloff K., Betts R. et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999, 18: 899-906.
  56. Wang Z., Tobler S., Roayaei J. et al. Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA. 2009, 301: 945-953.
  57. WHO. Influenza vaccines WHO position paper. WER. 2005, 80: 279-287.
  58. WHO. Vaccines against influenza WHO position paper - November 2012. WER. 2012, 87: 461-476.
  59. Wright P., Neumann G., Kawaoka Y. Orthomyxoviruses In: Fields Virology. Knipe D., Howley P. (ed.). Lippincot Williams and Wilkins, 2007.
  60. Zahradnik J., Kasel J., Martin R. et al. Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77 (H1N1) influenza virus vaccine. J. Med. Virol. 1983, 11: 277-285.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Kashirina O.S., Vasiliev Y.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies